Genenta Science SpA (GNTA) - Market Cap to Net Income Ratio

Corporate emblem and logo of Genenta Science (GNTA)

The financial price visualization for Genenta Science S.p.A. (GNTA) demonstrates a figure of -3.10. Currently, global conflicts are hindering the business by blocking cross-border trials and disrupting the transport of biosamples. However, Genenta Science S.p.A. (GNTA) is relying on the development of the Temferon system for transporting modulators into tissues, and its strategy is based on high treatment costs driven by unique cell programming to combat glioma.

GNTA genenta.com: Price to Earnings Ratio in the range 07/04/2022 - 11/04/2026

Comprehensive metric breakdowns and analytics for Genenta Science SpA (GNTA)

- market price and analyst price targets:
Market Price Genenta|GNTA - Analyst Consensus Forecast
- market capitalization indicators:
Market Capitalization Genenta Science S.p.A.|GNTA - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Net Asset Value per Share Genenta Science|GNTA - Company Net Assets|Market Value to Book Value genenta.com|GNTA - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Genenta Science S.p.A.|GNTA - Long-Term Debt to Capital|Current Liabilities to Capital Genenta|GNTA - Company Debts|Debt to Book Capitalization Ratio Genenta Science S.p.A.|GNTA - Company Long-Term Debt|Company Short-Term Debt Genenta Science|Intermediate Coverage Ratio genenta.com
- business earnings and investment ratios data:
GNTA - Net Profit|Projected Net Profit Genenta Science S.p.A.|GNTA - P/E Multiple|Projected Price to Earnings Ratio Genenta|GNTA - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Genenta Science S.p.A.|GNTA - Operating profit EBITDA|Net earnings per one share for the last twelve months Genenta Science|GNTA - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months genenta.com|GNTA - Net earnings per share growth this year|Projected earnings per share increase next year Genenta Science S.p.A.
Comprehensive company analysis:genenta.com
Signature product of Genenta Science

The specifics of gene therapy development at Genenta Science S.p.A. (GNTA), characterized by high clinical trial costs, make the issuer's P/E ratio a key indicator of market confidence in future earnings. The ratio of market capitalization to net income reflects the investment payback period, allowing for the timely diagnosis of systemic risks or asset undervaluation amid patent and regulatory uncertainties.

Analysis of competing companies

Market Cap to Earnings legendbiotech.com LEGN|P/E Multiple SANA|Autolus Therapeutics PLC (AUTL) - Market Cap to Net Income Ratio|Allogene Therapeutics Inc - Price to Earnings Ratio|Selecta Biosciences Inc. (RNAC) - Market Cap to Earnings|CLLS: Price to Earnings Ratio|Company Value to Net Income CRBU (cariboubio.com)|TIL: P/E Multiple|Price to Earnings Ratio Century Therapeutics, Inc.|JSPR (Jasper Therapeutics Inc) - P/E Multiple|Market Cap to Earnings Senti Biosciences Inc SNTI|Price to Earnings Ratio Adaptimmune (ADAP)|Price to Earnings Ratio CERO (cero.bio)|Price to Earnings Ratio Alaunos Therapeutics, Inc. TCRT|Achilles Therapeutics PLC - Price to Earnings Ratio|CRGX: Price to Earnings Ratio|Company Value to Net Income PSTX (Poseida Corp)|TSVT: P/E Multiple|Market Cap to Net Income Ratio gracellbio.com GRCL